Thank you for choosing to subscribe to Gileadâs investor email alert(s).
In order for us to validate your subscription and consent to opt-in for email alerts, please click on the following activation link:
https://investors.gilead.com/resources/investor-email-alerts/email-alert-activation/default.aspx?token=E306F9DD-53FF-49D6-9AFC-D14EA5E1ED59
If the link above is not clickable, please copy and paste it into your browser.
If you did not request an email subscription and are unsure of why you received this email - please contact [email protected].
Thank you,
Gilead Sciences, Inc.
In order for us to validate your subscription and consent to opt-in for email alerts, please click on the following activation link:
https://investors.gilead.com/resources/investor-email-alerts/email-alert-activation/default.aspx?token=E306F9DD-53FF-49D6-9AFC-D14EA5E1ED59
If the link above is not clickable, please copy and paste it into your browser.
If you did not request an email subscription and are unsure of why you received this email - please contact [email protected].
Thank you,
Gilead Sciences, Inc.
Date Sent: 1/8/2024 8:19:20 AM | Powered by Q4 Inc. |
-
This email was sent
January 8, 2024 1:19pm
-
Country:
United States
-
Tags
Biotechnology B2B